La Roche-Posay, introduces the new MELA B3 product range featuring L’Oréal’s biggest pigmentation innovation, Melasyl™. This breakthrough is the result of 18 years of research and the screening of over 100,000 molecules, leading to the discovery of this full-spectrum active ingredient in pigmentation science.
First presented at the World Congress of Dermatology 2023, Melasyl™ was unveiled alongside the results of a first-of-its-kind epidemiological study involving 48,000 participants from 34 countries across all continents. The study revealed a high prevalence of pigmentation disorders worldwide and a significant impact on quality of life and stigmatisation. Among the findings, 50% reported experiencing a form of pigmentation disorder such as Sun Spots, Post inflammatory Hyperpigmentation (PIH) and Melasma.
The MELA B3 product lineup heralds a new era in hyperpigmentation treatment, addressing a widespread skin concern that affects millions globally and profoundly impacts both appearance and mental well-being. In La Roche-Posay’s study, 22% of respondents felt less loved by family and friends, 19% felt that they have brought shame to their family and relatives and 20% felt pushed away by their partner due to the strong social stigmatisation linked to pigmentation disorders.
MELA B3 features key benefits such as anti-inflammation to reduce inflammation caused by UV exposure and pollution, skin renewal and exfoliation to promote cellular turnover and diminish dark spots, and antioxidant protection to shield against free radicals that stimulate melanin production.
As one of the most complex skin conditions to understand and treat, L’Oréal and La Roche Posay reached a breakthrough in the form of Melasyl™, a new molecule with unique mode of action to fight against pigmentation. This pioneering, multi-patented molecule boasts a unique mode of action by intercepting excess melanin before it even reaches the skin’s surface, trapping melanin precursors. This, in turn, delivers visible results in as little as one week.
Ashlee Ng, General Manager of L’Oréal Malaysia’s Dermatological Beauty Division, emphasised La Roche-Posay’s commitment to enhancing skin health through science-backed skincare and dermatological expertise. “La Roche-Posay has always been deeply rooted in dermatology. Partnering with dermatologists, we aim to stay at the forefront of skincare science and continue pioneering new breakthroughs for our consumers. The introduction of the MELA B3 product range, featuring Melasyl™, marks a significant step in this direction. We believe this new formulation will have a transformative impact on our consumers, providing a solution that not only addresses hyperpigmentation but also improves overall skin health.”
She added, “With the combination of Melasyl™, Niacinamide, and La Roche-Posay’s signature thermal spring water, the MELA B3 lineup is highly effective. Once consumers achieve their desired results, they can have peace of mind knowing that MELA B3 has been tested with anti relapse efficacy, significantly reducing the recurrence of hyperpigmentation. Additionally, our products are suitable for sensitive skin as each La Roche-Posay product has been tested extensively, ensuring safety and effectiveness. The L’Oréal Dermatological Beauty Division is proud to bring consumers access to such cutting-edge innovations.”
To help raise awareness on hyperpigmentation at the Mela B3 launch, Consultant Dermatologist, from Subang Jaya Medical Centre, Dr. Ch’ng Chin Chwen shared the various cause and effects of hyperpigmentation along with prevention measures. She also helped bust some myths surrounding hyperpigmentation to enlighten the audience about this skin condition.
Angeline Tay, Assistant Manager at L’Oreal Research & Innovation Singapore, also showcased the journey of developing Melasyl™. She explained how Melasyl™ targets pigmentation while respecting the individual’s natural skin tone and shared additional insights from L’Oreal’s pigmentation research.
Leading La Roche-Posay’s fight against hyperpigmentation is the MELA B3 Serum, offering a comprehensive solution suitable for all skin tones. This innovative formula combines Melasyl™ with 10% Niacinamide (Vitamin B3) and other potent ingredients to target key factors contributing to hyperpigmentation, such as:
- Anti-Inflammation: Reduces inflammation caused by UV exposure, pollution, and other environmental stressors.
- Skin Renewal & Exfoliation: Promotes cellular turnover to eliminate excess melanin and visibly diminish dark spots.
- Antioxidant Protection: Shields against free radicals that can stimulate melanin production.
- Dermo-Epidermal Junction Strengthening: Helps prevent melanin deposition in the dermis, addressing more challenging forms of hyperpigmentation.
The MELA B3 range is available at all leading pharmacies and e-commerce platforms. Powered by Melasyl™ and Niacinamide, La Roche-Posay presents a 3-step routine for those suffering the physical and mental effects of hyperpigmentation:
1. Begin with the new MELA B3 Clarifying Micro-Peeling Gel Cleanser. (RRP: RM89.90)
2. Follow with the MELA B3 Serum. (RRP: RM199.90)
3. Complete your routine with the new MELA B3 Cream SPF 30. (RRP: RM159.90)
To celebrate the revolution in pigmentation treatment, MELA B3 comes in a new, more luxurious and sensorial texture. The peach-colored gel feels incredibly light to the touch, offers high skin affinity for faster absorption, and is free from alcohol, ensuring no irritation.
